The FDA Is Making Biosimilars Easier to Approve. But Will Patients Actually Use Them?

Last week, the FDA released new draft guidance designed to streamline the development of biosimilar drugs by removing certain testing requirements. The goal is to accelerate competition and make biologic therapies more affordable. At first glance, this may appear to be a purely regulatory update. In reality, it highlights a much larger issue in healthcare. […]